Mark IV has recently done a project for Biocon . Bradia is a new cardiovascular drug launched in India for the first time by Biocon.
It is a If channel blocker and selectively decreases the heart rate without any other effect on the heart.
It thus reduces Anginal Attacks by more than 50 % and reduces the risk of fatal and nonfatal MI by 36 %.